Correlated Drug Terms (2)

---

	Name (Synonyms)	Correlation
drug1412	Information leaflet Wiki	1.00
drug3098	WALC-R Wiki	1.00

Correlated MeSH Terms (1)

---

	Name (Synonyms)	Correlation
D060825	Cognitive Dysfunction NIH	0.32

Correlated HPO Terms (1)

---

	Name (Synonyms)	Correlation
HP:0001268	Mental deterioration HPO	0.32

Primary Outcomes

Description: Time to treatment failure during the 28-day treatment period. Treatment failure is defined as additional or alternative treatment required, or intubation and invasive ventilation, or transfer to intensive care unit, or death.

Measure: Evaluation of EPA-FFA efficacy compared to standard of care

Time: 28 days

---

Secondary Outcomes

Description: Time to (in days) and number of days with oxygen saturation >95% without oxygen inhalation during the 28-day treatment period

Measure: Increase in oxygen saturation

Time: 28 days

---

Description: Time to (in days) and number of days with PaO2/FiO2 >300mmHg without oxygen inhalation during the 28-day treatment period

Measure: PaO2/FiO2 >300mmHg increase

Time: 28 days

---

Description: Change in IL-6 level during the 28-day treatment period

Measure: Reduction of IL-6

Time: 28 days

---

Description: To determine whether EPA-FFA gastro-resistant capsules decreases mortality rate during the study.

Measure: Mortality rate reduction

Time: throughout the study, about 3 months

---

Description: To determine whether EPA-FFA gastro-resistant capsules decreases ICU days during the study.

Measure: Reduction in ICU stays

Time: throughout the study, about 3 months

---

Description: To determine whether EPA-FFA gastro-resistant capsules decreases hospitalisation days during the study

Measure: Reducing hospitalisation days

Time: throughout the study, about 3 months

---

Description: To determine whether EPA-FFA gastro-resistant capsules decreases the need for invasive mechanical ventilation during the study

Measure: reduction in need for mechanical ventilation

Time: throughout the study, about 3 months

---

Description: Time to (in days) and number of days with fever normalization < 36.6°C armpit, < 37.2°C oral, < 37.8°C rectal, during the 28-day treatment period

Measure: Fever reduction

Time: 28 days

---

Other Outcomes

Description: To evaluate the safety of EPA-FFA gastro-resistant capsules in the treatment of COVID-19 (SARS-CoV-2) by assessing subjects clinical lab parameters and vital signs, and the number and proportion of subjects with AEs.

Measure: Safety - Vitals, AEs and Clinical lab parameters

Time: throughout the study, about 3 months

---